The core activity of iOnctura is the development of cancer drugs, particularly in oncology immunotherapy, with a focus on solid tumors, uveal melanoma and other types of cancer.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Oncology small-molecule programs against hard-to-treat, often neglected cancer types; focus on precisely targeted, orally dosed therapeutics with low toxicity.
Roginolisib (IOA-244)
Orally dosed PI3Kδ inhibitor in clinical development for uveal melanoma, NSCLC, myelofibrosis, CLL and PTCL; studied as monotherapy and in combination.
Cambritaxestat (IOA-289)
Orally dosed autotaxin inhibitor in clinical development for pancreatic and liver malignancies; studied in combination with chemotherapy.
IOA-359
Small molecule as a TGF-β signalling pathway inhibitor in development for solid tumors; designed for combination therapies against tumor resistance.
Clinical trials in oncology
Clinical trials in uveal melanoma, pancreatic cancer, NSCLC, myelofibrosis, CLL and PTCL with safety, efficacy and biomarker endpoints.